MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
50.10
+0.26
+0.52%
After Hours: 50.27 +0.17 +0.34% 19:57 07/18 EDT
OPEN
51.08
PREV CLOSE
49.84
HIGH
51.68
LOW
48.53
VOLUME
2.60M
TURNOVER
0
52 WEEK HIGH
99.41
52 WEEK LOW
8.28
MARKET CAP
5.52B
P/E (TTM)
-53.8420
1D
5D
1M
3M
1Y
5Y
1D
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company and Novo Nordisk A/S faced a significant selloff on Thursday. Shares of Eli Lilly plummeted by 6.3%, marking their worst daily performance since March 2021. New weight-loss drugs from rival pharmaceutical companies are threatening the dominance of the two giants.
Benzinga · 19h ago
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
NASDAQ · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Crypto Stocks, Industrial REITs
The Nasdaq tumbled more than 2% to a two-week low on Wednesday. Chip and tech stocks fell on the prospect of tighter China-focused U.S. Trade curbs. The Dow bucked the trend and jumped to a record high of 41,166.21.
Reuters · 1d ago
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
ASLAN Pharmaceuticals Limited's shares dipped 38.7% to $0.68 on Wednesday. The company's Singapore-incorporated subsidiary has filed for voluntary liquidation. Aptevo Therapeutics Inc. Shares climbed 84% after surging around 10% on Tuesday.
Benzinga · 1d ago
BUZZ-Obesity pill makers fall on early data from Roche's experimental drug
Obesity pill makers fall on early data from Roche's experimental drug Updates. Shares of Mounjaro and Zepbound maker Eli Lilly LLY.N fall 3% to $915.47. Swiss drugmaker Roche reported promising early-stage data from an experimental pill. Other obesity drug developers Structure Therapeutics and Viking Therapeutic also decline.
Reuters · 1d ago
FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion
Weight-loss drug market is estimated to be worth about $150 billion by the early 2030s. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are the leaders in the field. Several other drug developers are aiming to join the bandwagon. Pfizer, Roche and Carmot Therapeutics are among companies targeting the market.
Reuters · 2d ago
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Roche announced topline results from two arms of an ongoing Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity. Eli Lilly And Co, Novo Nordisk, and Viking Therapeutics stocks are trading lower on Wednesday. Earlier on Wednesday, Roche announced results from a similar study.
Benzinga · 2d ago
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Jim Cramer said Fortinet, Inc. Is not his favorite stock. He said Air Products and Chemicals is a better run company than Linde plc. Cramer recommended not selling Match Group, Inc (NASDAQ:MTCH) The "Mad Money" host said Costco is the best of the breed.
Benzinga · 2d ago
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.